This fifteen-lncRNAs risk signature can not only effectively predict the prognosis of gliomas, but also reflects clinicopathological factors (e.g., grade, chemotherapy status, 1p19q codeletion and IDH mutation status). This evidence concerns the gene IDH2 and central nervous system cancer.